Insider Breakfast Golden Triangle Breakfast Event

Professor Ruth Roberts was thrilled to be invited to speak at Business Insider’s recent Golden Triangle Breakfast Event at Alderley Park in the Northwest.  The new golden triangle is part of a vision to take the Cheshire Science Corridor and create a golden triangle in the Northwest to rival the original golden triangle of Oxford, Cambridge and London.

Joining Ruth, Director and Co-founder of ApconiX was Chris Doherty MD of Alderley Park, Peter Simpson CSO of the Medicines Discovery Catapult, CEO of the Knowledge Quarter in Liverpool, Mark Street-Docherty CEO of Elucigene Diagnostics, Julian Cobley MD of the Skills Growth Company (Cheshire East) and Cliff Kirby CEO of Needlesmart.

There was lively debate as the speakers considered the significance of digital health, tech and life sciences to the whole country not just the Northwest.  Competition is healthy, but the sector is collaborative in nature and sees collaboration with the all regions of the country to be of vital importance.  The Medicines Discovery Catapult are already working with Cambridge based Optibrium and Intellegens, having secured a £1M Innovate UK fund in September.

Inevitably BREXIT came up.  Europe is a large key market for any tech business.  Remaining relevant and at the cutting edge of innovation is fundamental to sustainability and growth.   Uncertainly remains the key issue going forward.   “I am also optimistic, because I am sure we will find a way.  Right now, though I don’t know how it will work,” commented Ruth.

Ultimately, though, biotech is an international market with global opportunities.  For many it is about working together, giving a consistent message and providing compelling offers that will attract companies and investors to the region.

By |2018-11-28T16:41:51+00:00November 29th, 2018|Events|Comments Off on Insider Breakfast Golden Triangle Breakfast Event

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.